Fulcrum Therapeutics, Inc. (FULC)

Fulcrum Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	41.15	26.66	36.19	36.5	58.14	97.81
Short-Term Investments	173.37	210.66	167.82	182.75	55.86	0
Cash & Cash Equivalents	214.52	237.31	204.01	219.25	114.01	97.81
Cash Growth	-28.24%	16.32%	-6.95%	92.32%	16.56%	32.37%
Receivables	0	0.54	0.23	3.64	2.53	0
Other Current Assets	3.44	4.35	3.28	3.11	2.97	2.28
Total Current Assets	217.95	242.2	207.52	226	119.51	100.08
Property, Plant & Equipment	11.45	12.39	15.97	7.37	8.4	9.21
Other Long-Term Assets	3.19	3.1	3.2	1.63	1.67	1.15
Total Long-Term Assets	14.64	15.5	19.17	9	10.07	10.36
Total Assets	232.59	257.69	226.69	235	129.58	110.44
Accounts Payable	3.86	2.76	3.64	4.79	4.08	2.19
Deferred Revenue	0	0	0.93	4.71	17.88	10
Current Debt	2.03	2.19	2.6	0	0	0
Other Current Liabilities	4.81	8.73	9.55	9.7	4.77	-0.05
Total Current Liabilities	10.69	13.68	16.73	19.2	26.73	12.14
Long-Term Debt	8.11	8.63	10.82	0	0	0
Other Long-Term Liabilities	0.2	0.2	0.2	4.26	7.67	11.15
Total Long-Term Liabilities	8.3	8.83	11.02	4.26	7.67	11.15
Total Liabilities	19	22.5	27.74	23.46	34.4	23.29
Total Debt	10.14	10.82	13.42	0	0	0
Debt Growth	-20.80%	-19.38%	-	-	-	-
Retained Earnings	-536.54	-509.67	-412.34	-302.47	-221.62	-150.8
Comprehensive Income	-0.43	-0.14	-0.8	-0.4	-0	0
Shareholders' Equity	213.59	235.19	198.94	211.54	95.18	87.15
Net Cash / Debt	204.38	226.49	190.59	219.25	114.01	97.81
Net Cash / Debt Growth	-28.57%	18.84%	-13.07%	92.32%	16.56%	32.37%
Net Cash Per Share	3.30	3.69	4.24	6.20	4.50	8.85
Working Capital	207.26	228.52	190.79	206.8	92.79	87.94
Book Value Per Share	3.45	3.84	4.42	5.98	3.75	7.89

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).